NCT04453722View on ClinicalTrials.gov

Prevention of Opioid-Induced Hypoxemia

CompletedOBSERVATIONAL
Enrollment

49

Participants

Timeline

Start Date

June 26, 2020

Primary Completion Date

April 30, 2022

Study Completion Date

June 15, 2023

Conditions
Non-cardiac Surgery
Interventions
DEVICE

Oxalert Monitor Mode

The investigator will evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO. Using the Oxalert in monitor only mode.

DEVICE

Oxalert Normal mode

The investigator will evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO using the Oxalert in monitor in normal mode

Trial Locations (1)

44195

Cleveland Clinic, Cleveland

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

The Cleveland Clinic

OTHER

NCT04453722 - Prevention of Opioid-Induced Hypoxemia | Biotech Hunter | Biotech Hunter